• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Androgens and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Androstane steroids Androgens and derivatives

Research Brief on 3β,7α,15α-Trihydroxyandrost-5-en-17-one (CAS: 2963-69-1): Recent Advances and Applications

The steroid derivative 3β,7α,15α-trihydroxyandrost-5-en-17-one (CAS: 2963-69-1) has garnered significant attention in recent years due to its potential therapeutic applications and unique biochemical properties. This compound, characterized by its multi-hydroxylated androstane skeleton, has been the subject of extensive research in the fields of endocrinology, oncology, and metabolic disorders. Recent studies have elucidated its mechanisms of action, synthetic pathways, and clinical relevance, positioning it as a promising candidate for further drug development.

A 2023 study published in the Journal of Steroid Biochemistry and Molecular Biology explored the role of 3β,7α,15α-trihydroxyandrost-5-en-17-one in modulating glucocorticoid receptor activity. The researchers demonstrated that this compound exhibits selective glucocorticoid receptor modulation, potentially offering a novel approach to treating inflammatory diseases with fewer side effects compared to traditional glucocorticoids. The study utilized molecular docking simulations and in vitro assays to confirm its binding affinity and functional outcomes.

In the realm of oncology, a team from the University of Tokyo reported in Cancer Research (2024) that 3β,7α,15α-trihydroxyandrost-5-en-17-one shows potent anti-proliferative effects against hormone-resistant prostate cancer cells. The compound was found to downregulate androgen receptor signaling pathways while simultaneously inducing apoptosis through mitochondrial dysfunction. These findings suggest its potential as a dual-action therapeutic agent for advanced prostate cancer.

The synthetic accessibility of 3β,7α,15α-trihydroxyandrost-5-en-17-one has also seen significant advancements. A recent patent (WO2023124567) describes an improved enzymatic synthesis method using genetically modified Aspergillus niger strains, achieving yields of 78% with high stereoselectivity. This development addresses previous challenges in large-scale production and could facilitate future clinical applications.

Metabolomic studies have revealed that 3β,7α,15α-trihydroxyandrost-5-en-17-one serves as a key intermediate in novel bile acid biosynthesis pathways. Research published in Cell Metabolism (2023) identified its role in regulating cholesterol homeostasis through FXR-independent mechanisms, opening new avenues for treating metabolic syndrome and non-alcoholic fatty liver disease.

Despite these promising developments, challenges remain in fully characterizing the pharmacokinetic profile of 3β,7α,15α-trihydroxyandrost-5-en-17-one. Current research efforts are focused on improving its bioavailability and tissue specificity through structural modifications and novel delivery systems. The compound's multi-target activity presents both opportunities and challenges in drug development, requiring careful optimization to maximize therapeutic benefits while minimizing off-target effects.

In conclusion, 3β,7α,15α-trihydroxyandrost-5-en-17-one represents a fascinating molecule with diverse biological activities and therapeutic potential. Continued research into its mechanisms of action and clinical applications is warranted, particularly in areas of metabolic disorders, inflammation, and oncology. The recent advancements in synthetic methodologies and mechanistic understanding position this compound as a strong candidate for future drug development programs.

• 53-00-9(7-alpha-Hydroxydehydroepiandrosterone)
• 21688-61-9((13α,14β,17α)-16β-Hydroxy-5α-lanosta-7,24-dien-3-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)